Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“Sacituzumab govitecan (SG) vs sacituzumab tirumotecan (Sac-TMT)
= antibody
≈ DAR (7.6 vs 7.4)
≠ conjugation chemistry (maleimide vs pyrimidine)
≈ linker (except conjugation part)
= carbonate cleavable group
≠ payload structure and properties (SN-38 vs KL610023).”
